AU
UK
CA
US
IND
NZ
Last update at 2026-06-03T18:50:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Income before tax | 9796.00M | 690.00M | 6859.00M | 5814.00M |
| Minority interest | 0.00000M | - | - | - |
| Net income | 8510.00M | 479.00M | 5664.00M | 4592.00M |
| Selling general administrative | 5709.00M | 5933.00M | 5537.00M | 5267.00M |
| Selling and marketing expenses | - | - | - | - |
| Gross profit | 23213.00M | 22503.00M | 21097.00M | 21624.00M |
| Reconciled depreciation | 2760.00M | - | - | - |
| Ebit | - | - | - | - |
| Ebitda | - | - | - | - |
| Depreciation and amortization | - | - | - | - |
| Non operating income net other | - | - | - | - |
| Operating income | 10022.00M | 1662.00M | 7605.00M | 7330.00M |
| Other operating expenses | - | - | - | - |
| Interest expense | 1024.00M | - | - | - |
| Tax provision | 1286.00M | 211.00M | 1247.00M | 1248.00M |
| Interest income | 573.00M | 970.00M | 735.00M | 1592.00M |
| Net interest income | -675.00000M | - | - | - |
| Extraordinary items | - | - | - | - |
| Non recurring | - | - | - | - |
| Other items | - | - | - | - |
| Income tax expense | - | - | - | - |
| Total revenue | 29443.00M | 28754.00M | 27116.00M | 27281.00M |
| Total operating expenses | 19421.00M | 27092.00M | 19511.00M | 19951.00M |
| Cost of revenue | 6230.00M | 6251.00M | 6019.00M | 5657.00M |
| Total other income expense net | -1230.00000M | - | - | - |
| Discontinued operations | - | - | - | - |
| Net income from continuing ops | 8510.00M | - | - | - |
| Net income applicable to common shares | 8510.00M | 480.00M | 5665.00M | 4592.00M |
| Preferred stock and other adjustments | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Total assets | 59023.00M | 58995.00M | 62125.00M | 63171.00M |
| Intangible assets | 16978.00M | 19948.00M | 26454.00M | 28894.00M |
| Earning assets | - | - | - | - |
| Other current assets | 1143.00M | - | - | - |
| Total liab | 36405.00M | 39665.00M | 39292.00M | 41931.00M |
| Total stockholder equity | 22618.00M | 19330.00M | 22833.00M | 21240.00M |
| Deferred long term liab | - | - | - | - |
| Other current liab | 2243.00M | - | - | - |
| Common stock | - | 1.00M | 1.00M | 1.00M |
| Capital stock | 1.00M | - | - | - |
| Retained earnings | 13730.00M | 11497.00M | 16304.00M | 15687.00M |
| Other liab | - | - | - | - |
| Good will | 8314.00M | 8314.00M | 8314.00M | 8314.00M |
| Other assets | 8239.00M | 6146.00M | 4792.00M | 4800.00M |
| Cash | 7564.00M | - | - | - |
| Cash and equivalents | 10605.00M | 9991.00M | 6085.00M | 5412.00M |
| Total current liabilities | 11813.00M | 12004.00M | 11280.00M | 11237.00M |
| Current deferred revenue | - | - | - | - |
| Net debt | 17372.00M | - | - | - |
| Short term debt | - | 0.00000M | 0.00000M | 0.00000M |
| Short long term debt | 2807.00M | - | - | - |
| Short long term debt total | - | - | - | - |
| Other stockholder equity | 22618.00M | 132.00M | 33.00M | 35.00M |
| Property plant equipment | 5606.00M | 5414.00M | 5317.00M | 5475.00M |
| Total current assets | 19886.00M | 19173.00M | 16085.00M | 14443.00M |
| Long term investments | 2974.00M | - | - | - |
| Net tangible assets | - | - | - | - |
| Short term investments | 2049.00M | 0.00000M | 1179.00M | 973.00M |
| Net receivables | 4913.00M | 4420.00M | 4660.00M | 4777.00M |
| Long term debt | 22129.00M | 24896.00M | 23189.00M | 22957.00M |
| Inventory | 4368.00M | 1710.00M | 1787.00M | 1507.00M |
| Accounts payable | 715.00M | - | - | - |
| Total permanent equity | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - |
| Additional paid in capital | - | - | - | - |
| Common stock total equity | - | - | - | - |
| Preferred stock total equity | - | - | - | - |
| Retained earnings total equity | - | - | - | - |
| Treasury stock | - | - | - | - |
| Accumulated amortization | - | - | - | - |
| Non currrent assets other | 4845.00M | - | - | - |
| Deferred long term asset charges | - | - | - | - |
| Non current assets total | 40681.00M | - | - | - |
| Capital lease obligations | - | - | - | - |
| Long term debt total | - | 24896.00M | 23189.00M | 22957.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Investments | -3163.00000M | - | - | - |
| Change to liabilities | - | - | - | - |
| Total cashflows from investing activities | - | -3449.00000M | -2265.00000M | -2466.00000M |
| Net borrowings | -1788.00000M | - | - | - |
| Total cash from financing activities | -7745.00000M | -3433.00000M | -5125.00000M | -6469.00000M |
| Change to operating activities | - | - | - | - |
| Net income | 8510.00M | 480.00M | 5613.00M | 4566.00M |
| Change in cash | -2428.00000M | 3906.00M | 673.00M | 74.00M |
| Begin period cash flow | 9991.00M | - | - | - |
| End period cash flow | 7564.00M | - | - | - |
| Total cash from operating activities | 10019.00M | 10828.00M | 8006.00M | 9072.00M |
| Issuance of capital stock | 408.00M | - | - | - |
| Depreciation | 2760.00M | 381.00M | 354.00M | 323.00M |
| Other cashflows from investing activities | - | -2926.00000M | -1680.00000M | -1738.00000M |
| Dividends paid | -4003.00000M | 3918.00M | 3809.00M | 3709.00M |
| Change to inventory | -1036.00000M | - | - | - |
| Change to account receivables | -367.00000M | - | - | - |
| Sale purchase of stock | -1922.00000M | -728.00000M | -768.00000M | -1087.00000M |
| Other cashflows from financing activities | - | -281.00000M | -278.00000M | -173.00000M |
| Change to netincome | - | - | - | - |
| Capital expenditures | 563.00M | 523.00M | 585.00M | 728.00M |
| Change receivables | - | - | - | - |
| Cash flows other operating | - | - | - | - |
| Exchange rate changes | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - |
| Change in working capital | -3948.00000M | -880.00000M | -2302.00000M | -1763.00000M |
| Stock based compensation | 894.00M | - | - | - |
| Other non cash items | 1504.00M | - | - | - |
| Free cash flow | 9456.00M | - | - | - |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences CDR (CAD Hedged) |
0.44 1.70% | 26.29 | 19.51 | 15.04 | 5.62 | 7.21 | 6.14 | 13.31 |
| NOVO Novo Nordisk CDR (CAD Hedged) |
-0.31 1.71% | 17.78 | 3.31 | 3.54 | 1.10 | 1.74 | 3.88 | 7.66 |
| MRK Merck CDR (CAD Hedged) |
-0.04 0.15% | 25.78 | 15.70 | 22.32 | 4.40 | 5.36 | 4.81 | 11.07 |
| AMGN Amgen CDR (CAD Hedged) |
0.62 2.53% | 25.12 | 24.19 | 15.65 | 5.06 | 21.36 | 6.30 | 13.69 |
| SNY Sanofi CDR (CAD Hedged) |
-0.13 0.68% | 19.09 | 3.25 | 1.53 | 0.34 | 0.22 | 2.33 | 8.73 |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
333 Lakeside Drive, Foster City, CA, United States, 94404
| Name | Title | Year Born |
|---|---|---|
| Mr. Daniel P. O'Day | Chairman & CEO | 1965 |
| Mr. Andrew D. Dickinson | Chief Financial Officer | 1970 |
| Ms. Johanna Mercier | Chief Commercial Officer | 1970 |
| Ms. Erin Burkhart | SVP, Controller & Principal Accounting Officer | 1979 |
| Ms. Jacquie Ross C.F.A. | Senior Vice President of Treasury and Investor Relations | NA |
| Ms. Keeley Wettan | Executive VP and General Counsel of Legal & Compliance | NA |
| Ms. Jyoti K. Mehra | Executive Vice President of Human Resources | 1976 |
| Dr. Linda Slanec Higgins Ph.D. | Senior Vice President of Research, Innovation & Portfolio | 1962 |
| Dr. Flavius Martin M.D. | Executive Vice President of Research | NA |
| Ms. Janet Dorling | Senior Vice President of Intercontinental Region & Global Patient Solutions | 1974 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...